Atherosclerotic cardiovascular (CV) disease (ASCVD) incidence and mortality rates are
declining in many countries in Europe, but it is still a major cause of morbidity and mortality …

Chronic kidney disease is a progressive disease with no cure and high morbidity and
mortality that occurs commonly in the general adult population, especially in people with …

Background The effects of empagliflozin in patients with chronic kidney disease who are at
risk for disease progression are not well understood. The EMPA-KIDNEY trial was designed …

Background Large trials have shown that sodium glucose co-transporter-2 (SGLT2)
inhibitors reduce the risk of adverse kidney and cardiovascular outcomes in patients with …

Background: Hyperkalemia increases risk of cardiac arrhythmias and death and limits the
use of renin-angiotensin-aldosterone system inhibitors and mineralocorticoid receptor …

Background Dapagliflozin reduces the risk of kidney failure and heart failure in patients with
chronic kidney disease. We aimed to investigate the effects of dapagliflozin on kidney …

Background Chronic kidney disease (CKD) is a common complication of type 2 diabetes
(T2D). Glucagon-like peptide-1 receptor agonists (GLP-1RAs) improve glycaemic control …

Health professionals are encouraged to take the Guidelines fully into account when
exercising their clinical judgment, as well as in the determination and the implementation of …

After the publication of the revised edition, therapeutic drugs described in “Future Treatment”
were approved and important evidence for pharmacologic therapy and nonpharmacologic …

Chronic kidney disease (CKD) is a devastating condition that is reaching epidemic levels
owing to the increasing prevalence of diabetes mellitus, hypertension and obesity, as well …